Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931, Cologne, Germany.
Laboratoire de physique de l'Ecole normale supérieure, CNRS, PSL University, Sorbonne Université, and Université Paris Cité, 75005, Paris, France.
Nat Commun. 2023 Nov 6;14(1):7137. doi: 10.1038/s41467-023-42906-y.
HIV-1 broadly neutralizing antibodies (bNAbs) are able to suppress viremia and prevent infection. Their induction by vaccination is therefore a major goal. However, in contrast to antibodies that neutralize other pathogens, HIV-1-specific bNAbs frequently carry uncommon molecular characteristics that might prevent their induction. Here, we perform unbiased sequence analyses of B cell receptor repertoires from 57 uninfected and 46 chronically HIV-1- or HCV-infected individuals and learn probabilistic models to predict the likelihood of bNAb development. We formally show that lower probabilities for bNAbs are predictive of higher HIV-1 neutralization activity. Moreover, ranking bNAbs by their probabilities allows to identify highly potent antibodies with superior generation probabilities as preferential targets for vaccination approaches. Importantly, we find equal bNAb probabilities across infected and uninfected individuals. This implies that chronic infection is not a prerequisite for the generation of bNAbs, fostering the hope that HIV-1 vaccines can induce bNAb development in uninfected people.
HIV-1 广谱中和抗体(bNAbs)能够抑制病毒血症并预防感染。因此,诱导其产生是一个主要目标。然而,与中和其他病原体的抗体不同,HIV-1 特异性 bNAbs 经常携带可能阻止其产生的罕见分子特征。在这里,我们对 57 名未感染和 46 名慢性 HIV-1 或 HCV 感染个体的 B 细胞受体库进行了无偏序列分析,并学习了概率模型来预测 bNAb 发展的可能性。我们正式表明,bNAb 较低的可能性预示着更高的 HIV-1 中和活性。此外,通过概率对 bNAbs 进行排序,可以识别出具有更高产生概率的高效抗体,作为疫苗接种方法的优先靶标。重要的是,我们发现感染和未感染个体的 bNAb 概率相等。这意味着慢性感染不是产生 bNAb 的先决条件,这增加了 HIV-1 疫苗能够在未感染人群中诱导 bNAb 产生的希望。